Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentavalent rotavirus vaccine bovine reassortant - Serum Institute of India

Drug Profile

Pentavalent rotavirus vaccine bovine reassortant - Serum Institute of India

Alternative Names: BRV-PV; LBRV-PV; Live attenuated bovine-human reassortant rotavirus vaccine; Rota-V-Aid™; ROTASIIL®

Latest Information Update: 15 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serum Institute of India
  • Developer Pharm Aid; Serum Institute of India
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections

Most Recent Events

  • 22 Feb 2019 Phase-III clinical trials in Rotavirus infections (In infants, Prevention) in Russia (PO) (NCT05032391)
  • 28 Sep 2018 Launched for Rotavirus infections (In infants, Prevention) in India (PO) before September 2018
  • 25 Jun 2018 Serum Institute of India completes a phase II/III trial in Rotavirus infections (Rotavirus gastroenteritis) (In volunteers, In infants, Prevention) in India (PO) (NCT03474055)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top